urea has been researched along with risperidone in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I | 1 |
Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK | 1 |
Brennan, JA; Comery, TA; Dunlop, J; Ghiron, C; Grauer, SM; Haydar, S; Jow, F; Kelley, C; Marquis, KL; Navarra, RL; Pulicicchio, C; Roncarati, R; Scali, C; Terstappen, GC | 1 |
Ball, SR; Bzdega, T; Der, EK; Farago, PR; Hark, TJ; Janczura, KJ; Lavin, KM; Lee, JC; Lee, MJ; Madore, JC; Neale, JH; Olszewski, RT; Profaci, CP | 1 |
Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM | 1 |
Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
1 review(s) available for urea and risperidone
Article | Year |
---|---|
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
1 trial(s) available for urea and risperidone
Article | Year |
---|---|
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Urea; Young Adult | 2012 |
5 other study(ies) available for urea and risperidone
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazoles; Catalepsy; Haloperidol; Intracellular Signaling Peptides and Proteins; Locomotion; Male; Naphthyridines; Neuropeptides; Olanzapine; Orexins; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Urea | 2007 |
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognition Disorders; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Male; Memory; Mice; Pyridines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptors, Nicotinic; Risperidone; Schizophrenia; Urea | 2011 |
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Glutamate Carboxypeptidase II; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Recognition, Psychology; Risperidone; Schizophrenia; Soman; Urea | 2012 |